Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03819101 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Study acronym: PEACE-4
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 23 to 30v6
  2. Primary completion date: Mar 2034 to Mar 2042
    • Study sites: 20 to 23
    • Study completion date: Mar 2038 to Mar 2042
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Site contacts updated at 6 of 20 sitesv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 20
    • Start date changed from estimate of Mar 2019 to Jun 6, 2019
    • Eligibility criteria revised
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a 2x2 factorial randomized, multicenter, international, open phase III trial. The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer starting first line treatment for CRPC
Trial Details
NCT Number NCT03819101
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Collaborators: National Cancer Institute, France
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 1,210 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov